Baclofen — research review 1

...and Baclofen, a GABA-B agonist used for spasticity and neuropathic pain, presents a fascinating intersection with aging research.

Right. While chronic pain itself is known to accelerate biological aging — for instance, a study in GeroScience 2025 found painful diabetic neuropathy linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy – Baclofen’s long-term effects aren't straightforward.

Precisely. The idea is that alleviating pain could theoretically slow that aging process. But when we look at Baclofen specifically, especially with prolonged use, the picture gets more complex regarding all-cause mortality and other biological markers.

Some studies hint at potential associations, but robust evidence directly linking Baclofen's long-term use to either accelerating or decelerating biological aging via epigenetic clocks, beyond its pain-relieving effects, is still emerging or not definitive.

It's crucial to distinguish. Baclofen can undeniably improve quality of life for those with severe spasticity or neuropathic pain, and that's a genuine benefit. But we're also talking about a medication with known side effects like sedation, potential for falls, and cognitive impact, which can themselves contribute to frailty in older adults.

Exactly. While some research explores Baclofen's impact on inflammation pathways, a known driver of aging, direct causal links between its use and, say, a measurable slowing of an epigenetic clock or a decrease in all-cause mortality, remain largely unproven.

So, it's a balancing act. The harm of untreated pain is real, potentially accelerating aging. The benefits of Baclofen for specific conditions are also real. But the idea that Baclofen itself acts as an anti-aging compound or definitively influences all-cause mortality beyond pain relief and its side effect profile, that’s not something the current evidence strongly supports. More research is definitely needed.